Brian C. O'Fahey

Bluejay Diagnostics in its US$8.8m and US$3.5m public offerings of common stock and warrants, its US$1.6m registered direct offering of common stock and warrants, and a US$2.3m private placement.

eMed in a 2-step tender offer and merger transaction by which it acquired Science 37 Holdings.

Conformis in its US$17.3m registered direct offering of common stock and warrants, US$85m underwritten public offering of common stock, and all-cash sale transaction with restor3d, Inc.

Orthofix Medical in a US$830m merger-of-equals with SeaSpine, US$140m sale of its sports medicine business, US$330m acquisition of a spinal implants business, and US$19m sale of its vascular business.

National Rural Utilities Cooperative Finance Corporation in multiple medium-term notes and collateral trust bond public offerings aggregating over several billion dollars.

Transurban in its US$2.1bn sale of a 50 percent interest in its Transurban Chesapeake assets, including multiple toll roads. 

NextEra Energy and Mendocino Capital, LLC in their purchases of US$100m in preferred stock and US$25m in common stock of OPAL Fuels Inc.

NextEra Energy in its US$1.5bn sale of its FPL FiberNet business to Crown Castle.

James Ayers in his US$102m underwritten public offering and sale of common stock in FB Financial Corporation through Keefe, Bruyette & Woods,, a Stifel Company

Novartis in its US$8.7bn acquisition of AveXis.

Orthofix Medical in its US$10m preferred stock and convertible notes investment in Neo Medical SA.

R&R Trucking and its members in its sale transaction with Daseke.

CereVasc in a US$44m Series A private placement equity financing transaction.

3M Company in its US$1bn acquisition of the Polypore separations media business.

Insulet in its US$345m convertible senior notes public offering.

The Advisory Board Company in its US$850m acquisition of Royall & Company.

Omnispace in its US$60m private placement equity financing.

Cytyc Corporation in its US$450m acquisition by tender offer of Adeza Biomedical Corporation, and subsequent US$6.2 billion sale to Hologic.

Constitution Medical in multiple private placement transactions with Warburg Pincus and its management team and founders in the company’s subsequent US$220m sale to Roche.

Insulet in the sale of its Neighborhood Diabetes subsidiary to Liberty Medical.

Katch and VM Holdings in multiple private placement equity issuances, the acquisitions of BrokersWeb and Web Dev and Katch’s subsequent exit sale transaction with MediaAlpha.

Oversee.net in its US$65m acquisition of Moniker, US$45m acquisition of SnapNames and OregonNames, and multiple subsequent asset divesture transactions.

ODN Holdings in its US$150m private placement of preferred stock to Oak Hill Capital Partners. 

Novoste Corporation in its (i) strategic alternatives process (ii) proposed merger with ONI Medical, and (iii) subsequent sale of its vascular brachytherapy business to Best Vascular.

Orthofix International in its corporate redomicile from Curaçao to the State of Delaware, and related registration statement on Form S-4.

Nabi Biopharmaceuticals in its US$250m cross-border business combination with Biota Holdings and its US$185m sale of its biologics division to Biotest Pharmaceuticals.

Independent directors, special committees, and audit committees in controlling stockholder transactions, internal and/or government investigations, restatements, and shareholder litigation.

Advertising.com in its US$435m acquisition by America Online.

An SEC-appointed monitor in connection with the court-supervised administration of GPB Capital and its related funds following the criminal indictment of its founder.

The boards of several companies in the defense of shareholder activism matters, including the negotiation of several cooperation agreements and the successful defense of a short slate proxy contest.

Multiple clients on their ESG reports and disclosures, and with respect to greenwashing risks.